Please enable Javascript
Daniel Tennenbaum, MD
Articles by Daniel Tennenbaum, MD
Trends in Managing Advanced and Metastatic Prostate Cancer
Daniel Tennenbaum, MD
Expert Interviews
|
December 19, 2022
Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer.
Read More
Survival Impact of Variant Histology Diagnosis in UTUC
Daniel Tennenbaum, MD
Journal
|
November 22, 2022
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features.
Read More
New Research in Phenotypic Precision Medicine
Andrew J. Armstrong, MD, ScM, FACP
RLT-PSMA
|
November 15, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on new research in phenotypic precision medicine.
View More
How Pain Can Serve as a Useful Biomarker for Prostate Cancer
Daniel Tennenbaum, MD
RLT-PSMA
|
October 27, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of pain in prostate cancer.
View More
Utility of PSMA-PET in Intermediate Risk Prostate Cancer: Part 2
Daniel Tennenbaum, MD
RLT-PSMA
|
October 25, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
View More
Utility of PSMA-PET in Intermediate Risk Prostate Cancer: Part 1
Daniel Tennenbaum, MD
RLT-PSMA
|
October 25, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
View More
Hereditary RCC: Presentations and Approaches to Treatment
Daniel Tennenbaum, MD
Journal
|
October 24, 2022
A guide to hereditary RCCs and their syndromes, as well as the relevant recommended guidelines for diagnosis and management.
Read More
How is Precision Medicine Utilized in Advanced Prostate Cancer?
Daniel Tennenbaum, MD
RLT-PSMA
|
October 3, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of precision medicine in prostate cancer.
View More
Review: A Decade of Robotic-Assisted Radical Nephrectomy With Inferior Vena Cava Thrombectomy
Daniel Tennenbaum, MD
Journal
|
September 27, 2022
Limited evidence of the feasibility of robot-assisted laparoscopic radical nephrectomy with IVC thrombectomy exists.
Read More
Should Patients With a Family History of Cancer Be Excluded From Active Surveillance?
Daniel Tennenbaum, MD
Journal
|
August 24, 2022
A report examines the correlation between family history of prostate cancer and risk of progression after prostatectomy.
Read More
En Bloc Versus Conventional Transurethral Resection of Bladder Tumors
Daniel Tennenbaum, MD
Journal
|
July 27, 2022
The standard of care transurethral resection for bladder tumors is compared with en bloc resections for urologic procedures.
Read More
Editor’s Talk: Triplet Versus Doublet Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Daniel Tennenbaum, MD
Journal
|
June 24, 2022
Professor Catherine Marshall gives insight on the recent shifts in management of mHSPC and compares therapies.
Read More
Identification of Potential Predictor of Biochemical Recurrence in Prostate Cancer
Daniel Tennenbaum, MD
RLT-PSMA
|
May 20, 2022
Early identification of biochemical recurrence is a major challenge for post-radical prostatectomy surveillance.
Read More
Progress in the drug encapsulation of poly(lactic-co-glycolic acid) and folate-decorated poly(ethylene glycol)-poly(lactic-co-glycolic acid) conjugates for selective cancer treatment
Daniel Tennenbaum, MD
RLT-PSMA
|
May 20, 2022
This article presents an account of the literature on PLGA-based conjugates.
Read More
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis
Daniel Tennenbaum, MD
mCSPC
|
May 20, 2022
The treatment of CSPC has been revolutionized by the advent of apalutamide and enzalutamide in this setting.
Read More
68Ga-PSMA-PET/MRI Beneficial for Primary Staging of Prostate Cancer
Daniel Tennenbaum, MD
RLT-PSMA
|
December 10, 2021
Diagnostic accuracy of 68Ga-PSMA-PET/MRI is comparable with mpMRI for patients undergoing primary staging of prostate cancer.
Read More
18F-PSMA-1007 IDs Pathologic Lesions After Radical Prostatectomy
Daniel Tennenbaum, MD
RLT-PSMA
|
December 10, 2021
18F-PSMA-1007 PET/CT successfully detects pathological lesions in patients with high PSA levels after radical prostatectomy.
Read More
18F-PSMA-1007 Identifies Distant Metastases in Prostate Cancer
Daniel Tennenbaum, MD
RLT-PSMA
|
December 10, 2021
Researchers say 18F-PSMA-1007 PET/CT can identify distant metastasis in prostate cancer.
Read More
Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences
Daniel Tennenbaum, MD
RLT-PSMA
|
June 30, 2021
This article was originally published here. ...
Read More
Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
Daniel Tennenbaum, MD
RLT-PSMA
|
June 30, 2021
This article was originally published here. ...
Read More